Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C7H10N3O6S.Na |
Molecular Weight | 287.226 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].NC(=O)[C@@H]1CC[C@@H]2C[N@]1C(=O)N2OS([O-])(=O)=O
InChI
InChIKey=RTCIKUMODPANKX-JBUOLDKXSA-M
InChI=1S/C7H11N3O6S.Na/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15;/h4-5H,1-3H2,(H2,8,11)(H,13,14,15);/q;+1/p-1/t4-,5+;/m1./s1
Avibactam (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, covalent, slowly reversible β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes. The combination of ceftazidime with avibactam exhibited broad-spectrum activity against Ambler class A- and class C-producing Enterobacteriaceae. AVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam indicated for the treatment of patients with the following infections caused by designated susceptible microorganisms: Complicated Intra-abdominal Infections, used in combination with metronidazole and Complicated Urinary Tract Infections, including Pyelonephritis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2364670 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23371303 |
8.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | AVYCAZ Approved UseAVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam, a beta-lactamase inhibitor, indicated for the treatment of patients 18 years or older with the following infections caused by designated susceptible microorganisms: complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole and complicated Urinary Tract Infections (cUTI), including Pyelonephritis. Launch Date2015 |
|||
Curative | AVYCAZ Approved UseAVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam, a beta-lactamase inhibitor, indicated for the treatment of patients 18 years or older with the following infections caused by designated susceptible microorganisms: complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole and complicated Urinary Tract Infections (cUTI), including Pyelonephritis. Launch Date2015 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.6 mg/L |
0.5 g 3 times / day multiple, intravenous dose: 0.5 g route of administration: Intravenous experiment type: MULTIPLE co-administered: CEFTAZIDIME |
AVIBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
15.2 mg/L |
0.5 g single, intravenous dose: 0.5 g route of administration: Intravenous experiment type: SINGLE co-administered: Ceftazidime |
[NO STEREO] AVE-1330A FREE ACID|[NO STEREO] AVIBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
38.2 mg × h/L |
0.5 g 3 times / day multiple, intravenous dose: 0.5 g route of administration: Intravenous experiment type: MULTIPLE co-administered: CEFTAZIDIME |
AVIBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
42.1 mg × h/L |
0.5 g single, intravenous dose: 0.5 g route of administration: Intravenous experiment type: SINGLE co-administered: Ceftazidime |
[NO STEREO] AVE-1330A FREE ACID|[NO STEREO] AVIBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.71 h |
0.5 g 3 times / day multiple, intravenous dose: 0.5 g route of administration: Intravenous experiment type: MULTIPLE co-administered: CEFTAZIDIME |
AVIBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.22 h |
0.5 g single, intravenous dose: 0.5 g route of administration: Intravenous experiment type: SINGLE co-administered: Ceftazidime |
[NO STEREO] AVE-1330A FREE ACID|[NO STEREO] AVIBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
93% |
0.5 g single, intravenous dose: 0.5 g route of administration: Intravenous experiment type: SINGLE co-administered: Ceftazidime |
[NO STEREO] AVE-1330A FREE ACID|[NO STEREO] AVIBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1000 mg 3 times / day multiple, intravenous Highest studied dose Dose: 1000 mg, 3 times / day Route: intravenous Route: multiple Dose: 1000 mg, 3 times / day Sources: |
healthy, 18–45 years n = 6 Health Status: healthy Age Group: 18–45 years Sex: M Population Size: 6 Sources: |
|
2000 mg single, intravenous Highest studied dose Dose: 2000 mg Route: intravenous Route: single Dose: 2000 mg Sources: |
healthy, 18–45 years n = 6 Health Status: healthy Age Group: 18–45 years Sex: M Population Size: 6 Sources: |
|
500 mg single, oral |
healthy, 28.9 years n = 8 Health Status: healthy Age Group: 28.9 years Sex: M Population Size: 8 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 21.0 |
no | |||
Page: 21.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206494Orig1s000CllinPharmR.pdf#page=38 Page: 38.0 |
no | |||
Page: 21.0 |
no | |||
Page: 21.0 |
no | |||
Page: 21.0 |
no | |||
Page: 21.0 |
no | |||
Page: 21.0 |
no | |||
Page: 21.0 |
no | |||
Page: 21.0 |
no | |||
Page: 21.0 |
no | |||
Page: 21.0 |
no | |||
Page: 21.0 |
no | |||
Page: 21.0 |
no | |||
Page: 21.0 |
no | |||
Page: 21.0 |
no | |||
Page: 21.0 |
no | |||
Page: 21.0 |
no | |||
Page: 21.0 |
no | |||
Page: 21.0 |
no | |||
Page: 21.0 |
no | |||
Page: 21.0 |
no | |||
Page: 21.0 |
no | |||
Page: 21.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206494Orig1s000CllinPharmR.pdf#page=38 Page: 38.0 |
no | |||
Page: 21.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206494Orig1s000CllinPharmR.pdf#page=38 Page: 38.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206494Orig1s000CllinPharmR.pdf#page=38 Page: 38.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206494Orig1s000CllinPharmR.pdf#page=38 Page: 38.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206494Orig1s000CllinPharmR.pdf#page=38 Page: 38.0 |
no | |||
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206494Orig1s000PharmR.pdf#page=18 Page: 18.0 |
Sample Use Guides
AVYCAZ 2.5 grams (ceftazidime 2 grams and avibactam 0.5 grams) for injection administered every 8 hours by intravenous (IV) infusion over 2
hours in patients 18 years of age and older with creatinine clearance (CrCl) greater than 50 mL/min. For treatment of Complicated Intra-abdominal Infections (cIAI), metronidazole should be given concurrently. Recommended duration of treatment: cIAI: 5 to 14 days, Complicated Urinary Tract Infections (cUTI) including pyelonephritis: 7 to 14 days.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15254025
MICs of ceftazidime/AVE1330A(avibactam) for Enterobacteriaceae were at least eight-fold lower than those of ceftazidime alone. All of the Escherichia coli, Klebsiella pneumoniae, Citrobacter and Proteus mirabilis strains, including ceftazidime-resistant isolates, were inhibited at 4-8 mg/L. Only 2 mg/L were required to inhibit other Proteeae, Enterobacter, Salmonella and Serratia.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C258
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB179984
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
C142942
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
CHEMBL1689063
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
1603833
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | RxNorm | ||
|
85982
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
1383922-24-4
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
SUPERSEDED | |||
|
m2148
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000166051
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
1192491-61-4
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
DB09060
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
DTXSID701027694
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
85984
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
24944097
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
9V824P8TAI
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
9V824P8TAI
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD